日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The Tailored Biosimilar Approach: Expectations and Requirements

定制化生物类似药策略:预期与要求

Guillen, Elena; Barry, Sean; Jost, Nils; Ekman, Niklas; Knippel, Verena; Kuhlmann-Gottke, Johanna; Maier, Julia; Weise, Martina; Laslop, Andrea; Anour, René; van Zandbergen, Ger; Kirsch-Stefan, Nadine

Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?

生物类似药的监管决策中,临床疗效试验的结果重要吗?

Kirsch-Stefan, Nadine; Guillen, Elena; Ekman, Niklas; Barry, Sean; Knippel, Verena; Killalea, Sheila; Weise, Martina; Wolff-Holz, Elena

Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience

生物类似药的监管评价:基于科学证据和临床经验的原则完善

Kurki, Pekka; Kang, Hye-Na; Ekman, Niklas; Knezevic, Ivana; Weise, Martina; Wolff-Holz, Elena

Multiple angiopoietin recombinant proteins activate the Tie1 receptor tyrosine kinase and promote its interaction with Tie2.

多种血管生成素重组蛋白激活Tie1受体酪氨酸激酶,并促进其与Tie2的相互作用

Saharinen Pipsa, Kerkelä Katja, Ekman Niklas, Marron Marie, Brindle Nicholas, Lee Gyun Min, Augustin Hellmut, Koh Gou Young, Alitalo Kari

Bmx tyrosine kinase transgene induces skin hyperplasia, inflammatory angiogenesis, and accelerated wound healing

Bmx酪氨酸激酶转基因诱导皮肤增生、炎症性血管生成和加速伤口愈合

Paavonen, Karri; Ekman, Niklas; Wirzenius, Maria; Rajantie, Iiro; Poutanen, Matti; Alitalo, Kari